This study investigates the variables affecting indigenous pharmaceutical firms' (IPC) adoption of Good Distribution Practices (GDP) in Nigeria and Ireland. The study sheds light on the opportunities and problems related to GDP implementation by contrasting the viewpoints of experts with expertise in these two very different situations. There were 92 responses to the online survey questions (82) and phone interviews (10) used to collect the data. According to the report, both Nigeria and Ireland confront problems with their infrastructure, finance, and regulatory frameworks that make it difficult for local pharmaceutical companies to apply GDP recommendations effectively. Notably, the study discovered that while both countries face comparable issues, subtle differences in the scope and character of those challenges are introduced by the distinctive developmental landscapes of Nigeria and Ireland. The study stressed the role that legal frameworks have in encouraging GDP compliance and identified that regulatory inconsistency and gaps could cause implementation difficulties in both nations. This emphasises the significance of collaboration across regulatory organisations, such as Nigeria's NAFDAC and Ireland's HPRA, to harmonise methods to foster the adoption of more efficient guidelines. The study also demonstrated the crucial part that training and education play in establishing workforce competency and awareness of GDP requirements. Among the information gathered were suggestions for improving GDP implementation by resolving the identified difficulties hindering the implementation of Good Distribution Practices by indigenous pharmaceutical companies.